"AIDS TREATMENT NEWS" online - New Issue #340
----------------------------------------------------------------------
Latest issue has been added to the complete "AIDS Treatment News" archive on
AIDS.ORG
http://www.aids.org
********************
--- New issue features:
* AIDS Practice Issues Today: Interview with Paul Bellman, MD
* South Africa "AIDS Dissident" Dispute: Time to Stop and Think
* Pfizer Will Donate Fluconazole to South Africa
* New York: Immune-Based Therapies Teach-In, April 15
********************
You can read this and every previous issue of "AIDS Treatment News" at
http://www.aids.org
The "AIDS Treatment News" archive also includes a search engine to simplify
access to over 13 years of articles. Also featured is John S. James' helpful
personal index.
====================================================
*** About AIDS TREATMENT NEWS ***
====================================================
AIDS TREATMENT NEWS is a primary treatment resource for AIDS and HIV. It
reports on experimental and standard treatments, especially those available
now, and has been published twice monthly, continuously since 1986 by John S.
James.
AIDS TREATMENT NEWS interviews physicians, scientists, other health
professionals, and persons with AIDS or HIV, and collects information from
meetings and conferences, medical journals, and computer databases. Long-term
survivors have usually tried many different treatments, and found combinations
which work for them. AIDS TREATMENT NEWS does not recommend particular
therapies, but seeks to increase the options available.
AIDS TREATMENT NEWS is funded by subscriptions and contributions and does not
accept contributions from pharmaceutical companies or others whose products
they might cover.
------------------
Phone: (415) 255-0588 or (800) TREAT-1-2; Fax (415) 255-4659
Email: aidsnews at aidsnews.org
-----------------------------------------------------------------------------
* AIDS.ORG - a Worldwide AIDS Organization [non profit]
* http://www.aids.org
-----------------------------------------------------------------------------
